Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1401 PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment
Compose a Response to This Article
Other responses
No responses have been published for this article.
